PEOPLE - Arterial Remodeling Technologies makes appointment:
This article was originally published in Clinica
Stent developer Arterial Remodeling Technologies (ART - Noisy le Roi, France) has appointed Michael Van Der Leest as CEO. He joins from Minvasys (bifurcation devices) where he was director of R&D and regulatory affairs. ART has recently leased a manufacturing facility to produce bioesorbable stents and will leverage Mr Van Der Leest's expertise in development, regulatory, clinical, marketing and market dynamics.
You may also be interested in...
Australia’s competition regulator, the ACCC, has granted a conditional dispensation to allow generics industry association the GBMA and brand body Medicines Australia to work together to help address the coronavirus pandemic by sharing information on stock, inventory, manufacturing and the supply chain. However, tender pricing will not be among the subjects discussed.
The UK biotech's CEO tells Scrip that Izana's objective is to treat rapidly deteriorating COVID-19 patients before ICU admission and prior to ventilation.
Exclusive: HBW Insight speaks to HRA Pharma CEO David Wright about the company's plans to become a top-10 global OTC player. Wright reveals that HRA is about to enter Latin America, beginning with Mexico and Brazil, and is currently looking at at least two significant acquisitions to ramp up its expansion plans in the coming months.